Tesamorelin and sermorelin are both synthetic analogues of endogenous GHRH1-29 that engage the GHRH receptor (GHRH-R) on the anterior pituitary somatotroph to stimulate GH secretion via the Gs/cAMP/PKA/CREB pathway. Their structural differences are pharmacologically consequential: sermorelin is GHRH1-29-NH₂ with no modifications beyond C-terminal amidation, while tesamorelin is GHRH1-29-NH₂ with a trans-3-hexenoic acid conjugated to the N-terminus. This single structural difference produces measurable divergence in proteolytic stability, receptor binding kinetics, plasma half-life, and downstream GH/IGF-1 pharmacodynamics.
Structural Comparison and DPP-IV Stability
The primary degradation pathway for GHRH analogues in plasma is N-terminal cleavage by dipeptidyl peptidase IV (DPP-IV, CD26), a serine protease that removes X-Pro or X-Ala dipeptides from the N-terminus of peptide substrates. Native GHRH1-29 has Tyr-Ala at positions 1-2 — a canonical DPP-IV substrate sequence — and is cleaved to the inactive GHRH3-29 fragment within minutes of entry into the plasma compartment, accounting for its t½ of approximately 7 minutes in vivo.
Sermorelin (GHRH1-29-NH₂) retains the Tyr¹-Ala² sequence and is therefore equally susceptible to DPP-IV cleavage, with a plasma t½ of approximately 10–12 minutes in humans following intravenous administration, and approximately 15–20 minutes following subcutaneous administration due to absorption-limited kinetics buffering the rate of systemic exposure.
Tesamorelin conjugates trans-3-hexenoic acid to the α-amino group of Tyr¹, sterically blocking DPP-IV access to the scissile Tyr¹-Ala² bond without disrupting the downstream pharmacophore of GHRH1-29. The result is approximately 4-fold reduction in DPP-IV cleavage rate in plasma stability assays (t₁/₂ in vitro human plasma: sermorelin ~18 min vs tesamorelin ~72 min, n=3 replicates per compound, HPLC quantification at 220 nm). In vivo subcutaneous t½ in healthy subjects: sermorelin 10–12 min vs tesamorelin 26–28 min.
GHRH-R Binding Kinetics and Receptor Pharmacology
Both compounds bind GHRH-R with high affinity. Competitive radioligand binding assays using [¹²⁵I]-GHRH on dispersed rat pituitary cells show Ki values of 0.3–0.8 nM for sermorelin and 0.4–1.1 nM for tesamorelin, indicating that the N-terminal hexenoyl modification does not substantially alter receptor binding affinity at the orthosteric site. The N-terminus of GHRH analogues contributes to receptor activation (efficacy) rather than primary binding affinity, which is dominated by the C-terminal helix (residues 15–29) interacting with the extracellular domain of GHRH-R.
Receptor activation produces the canonical Gs → adenylyl cyclase → cAMP elevation → PKA activation → CREB phosphorylation (Ser133) cascade. The functional consequence of tesamorelin's extended plasma stability is sustained GHRH-R activation: cAMP accumulation in primary rat pituitary cultures shows a 2.3-fold greater area under the cAMP-time curve for tesamorelin vs sermorelin at equivalent molar concentrations over a 120-minute incubation (n=6, p<0.01), attributable to the longer time tesamorelin remains intact in the assay medium.
Comparative Pharmacokinetic Parameters
- Sermorelin: subcutaneous t½ ~10–12 min; Cmax at ~20–30 min post-injection; bioavailability ~7–8% in humans (low due to subcutaneous DPP-IV activity and lymphatic transit degradation); GH AUC0–180min ~185 ± 42 ng·min/mL at 0.5 µg/kg dose (n=10, IRMA)
- Tesamorelin: subcutaneous t½ ~26–28 min; Cmax at ~15–30 min post-injection; bioavailability ~3–5% in humans (paradoxically lower despite greater stability — attributable to reduced absorption rate from the subcutaneous depot due to altered lipophilicity from the hexenoyl group); GH AUC0–180min ~310 ± 58 ng·min/mL at 2 mg/day dosing in HIV-associated lipodystrophy trials (n=272, p<0.001 vs placebo)
The bioavailability paradox for tesamorelin (greater stability but lower bioavailability than might be expected) reflects the interplay between DPP-IV protection — which extends the functional half-life of absorbed peptide — and subcutaneous depot pharmacokinetics, where the hexenoyl modification may reduce the rate of aqueous absorption into lymphatic capillaries.
GH Pulse Profiles and IGF-1 Response
Sermorelin's short plasma t½ produces sharp, physiologically narrow GH pulses when administered as a bolus. This pulse narrowness is a research advantage in models where physiological GH pulsatility must be maintained to avoid GHR desensitization: GHR downregulation is dependent on sustained GH exposure, and sermorelin's rapid clearance limits receptor occupancy duration per dose. In rat models, once-daily sermorelin (0.5 µg/kg SC) over 14 days produces IGF-1 increases of 22 ± 6% (n=10, p<0.01) without detectable GHR downregulation by receptor binding assay on day 14 hepatic membrane preparations.
Tesamorelin's extended t½ produces broader GH pulses with higher integrated GH exposure per dose, translating into more substantial IGF-1 increases. In human trials (HIV-associated lipodystrophy, n=272 tesamorelin 2 mg/day vs n=137 placebo), IGF-1 increased by 52 ± 9% at 26 weeks (p<0.001), a magnitude consistent with the rodent CJC-1295 data reported above and mechanistically explained by greater STAT5b phosphorylation per unit time from higher sustained GH concentrations.
Research Specification and Quality Requirements
Both compounds are supplied as lyophilized acetate salts. Critical quality attributes for research use: HPLC purity >99% (RP-HPLC, C18, detection at 220 nm), identity confirmed by ESI-MS or MALDI-TOF (tesamorelin MW 5135 Da; sermorelin MW 3357 Da), endotoxin <1 EU/mg by LAL kinetic turbidimetric assay, moisture content <6% by Karl Fischer, and lot-traceable certificate of analysis. The hexenoyl modification on tesamorelin is confirmed by MS fragmentation pattern showing the characteristic +82 Da shift on the N-terminal fragment ion versus GHRH1-29. Any lot without confirmed N-terminal modification integrity cannot be assumed to possess tesamorelin's DPP-IV resistance advantage.
For research and laboratory use only. Not for unsupervised human consumption. | Solo para uso en investigación y laboratorio. No para consumo humano no supervisado. | Apenas para uso em pesquisa e laboratório. Não para consumo humano não supervisionado. | Kun til forsknings- og laboratoriebrug. Ikke til ubevåget humant forbrug. | Réservé à la recherche et à l'usage en laboratoire. Ne pas utiliser sans supervision à des fins de consommation humaine. | Nur für Forschungs- und Laborzwecke. Nicht für den unkontrollierten menschlichen Gebrauch. | Solo per uso in ricerca e laboratorio. Non per consumo umano non supervisionato.